Featured Publications
Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022
Bajema K, Wang X, Hynes D, Rowneki M, Hickok A, Cunningham F, Bohnert A, Boyko E, Iwashyna T, Maciejewski M, Viglianti E, Streja E, Yan L, Aslan M, Huang G, Ioannou G. Early Adoption of Anti–SARS-CoV-2 Pharmacotherapies Among US Veterans With Mild to Moderate COVID-19, January and February 2022. JAMA Network Open 2022, 5: e2241434. PMID: 36367727, PMCID: PMC9652752, DOI: 10.1001/jamanetworkopen.2022.41434.Peer-Reviewed Original ResearchConceptsCOVID-19 pharmacotherapySevere COVID-19SARS-CoV-2Health care systemCohort studyRisk factorsCare systemMedical conditionsCOVID-19Positive SARS-CoV-2 testVeterans Affairs Health Care SystemCOVID-19-related hospitalizationCOVID-19-related symptomsLarge integrated health care systemSARS-CoV-2 testVA health care systemIntegrated health care systemNon-Hispanic veteransModerate COVID-19Odds of receiptMultivariable logistic regressionCOVID-19 vaccinationMedical comorbiditiesMedian ageAnti-SARS
2023
Comparing histology between prostate cognitive fusion targeted biopsy and radical prostatectomy: exploring risk factors of Gleason score upgrading in Chinese patients
Zheng T, Sun H, Tang Y, Bi K, Zeng Y, Wang J, Yan L. Comparing histology between prostate cognitive fusion targeted biopsy and radical prostatectomy: exploring risk factors of Gleason score upgrading in Chinese patients. Journal Of Cancer Research And Clinical Oncology 2023, 149: 18029-18037. PMID: 37979056, DOI: 10.1007/s00432-023-05506-3.Peer-Reviewed Original ResearchDecision curve analysisMultivariable logistic regression analysisBiopsy Gleason scoreGleason scoreLogistic regression analysisChinese patientsRadical prostatectomyCOG-TBProstate volumeTumor locationRisk factorsTumor percentageBiopsy tissuePostoperative Gleason scorePatient treatment decisionsRegression analysisEffective treatment planPathological predictorsExcellent discriminatory powerTreatment decisionsCognitive fusionPatientsTreatment planSignificant associationDiscriminatory power